Bluechiip Ltd (ASX: BCT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Bluechiip Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $29.89 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 597.88 million
Earnings per share -0.005
Dividend per share N/A
Year To Date Return -4.08%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Bluechiip Ltd (ASX: BCT)
Latest News

BCT ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Bluechiip Ltd

Bluechiip Ltd is engaged in the development and commercialization of a wireless tracking solution. It serves healthcare and life science, security, defence, and manufacturing industries. Its product includes Retrofit Button For CryoVials; CryoVial Box; CryoTag; Matchbox Reader; Multi-Vial Reader; Hand-Held Reader; Stream Sample-Management Software; Blood Cassettes; and Towers/Racks/Frames.

BCT Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
17 Jan 2022 $0.05 $0.00 0.00% 2,821,647 $0.05 $0.05 $0.05
14 Jan 2022 $0.05 $0.00 0.00% 462,452 $0.05 $0.05 $0.05
13 Jan 2022 $0.05 $0.00 0.00% 490,669 $0.05 $0.05 $0.05
12 Jan 2022 $0.05 $0.00 0.00% 57,869 $0.05 $0.05 $0.05
11 Jan 2022 $0.05 $0.00 0.00% 212,419 $0.05 $0.05 $0.05
10 Jan 2022 $0.05 $0.00 0.00% 351,556 $0.05 $0.05 $0.05
07 Jan 2022 $0.05 $0.00 0.00% 351,887 $0.05 $0.05 $0.05
06 Jan 2022 $0.05 $0.00 0.00% 627,153 $0.05 $0.05 $0.05
05 Jan 2022 $0.05 $0.00 0.00% 71,566 $0.05 $0.05 $0.05
04 Jan 2022 $0.05 $0.00 0.00% 183,700 $0.05 $0.05 $0.05
31 Dec 2021 $0.05 $0.00 0.00% 197,971 $0.05 $0.05 $0.05
30 Dec 2021 $0.05 $0.00 0.00% 70,363 $0.05 $0.05 $0.05
29 Dec 2021 $0.05 $0.00 0.00% 325,497 $0.05 $0.05 $0.05
24 Dec 2021 $0.05 $0.00 0.00% 552,406 $0.05 $0.05 $0.05
23 Dec 2021 $0.05 $0.00 0.00% 382,415 $0.05 $0.05 $0.05
22 Dec 2021 $0.05 $0.00 0.00% 544,387 $0.05 $0.05 $0.04
21 Dec 2021 $0.05 $0.00 0.00% 861,220 $0.05 $0.05 $0.05

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
01 Apr 2021 Andrew McLellan Transfer 2 $109,164
Off-market transfer.
01 Apr 2021 Andrew McLellan Transfer 2 $109,164
Off-market transfer. As per announcement on 09/04/2021.
19 Mar 2021 Andrew McLellan Issued 2 $111,963
Conversion of securities.
19 Mar 2021 Andrew McLellan Expiry 128 $4,880
As advised by the company. 2,099,602 - Performance Rights
As per announcement on 26/03/2021.
Performance Rights have lapsed.
19 Mar 2021 Andrew McLellan Exercise 2 $111,963
Conversion of securities. 2,340,182 - Performance Rights

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Iain MacGregor Crawford Kirkwood Non-Executive DirectorNon-Executive Chairman Nov 2007
Mr Kirkwood is an experienced private consultant, investor and non-executive Director. He has practical and operational experience gained from a successful financial career spanning 35 years in a range of industries including auditing, resources, manufacturing and latterly healthcare in Australia, Britain and the USA. He started his career at Arthur Andersen & Co in London. During his career, he has held a range of senior financial and general management positions, including Woodside Petroleum Limited, Santos Limited, Pilkington plc, F.H. Faulding & Co Limited and Clinuvel Pharmaceuticals Limited. During the past three (3) years he has also served as a Director of the ASX listed company, Simonds Group Limited (Appointed 20 September 2017).
Mr Michael B. Ohanessian Non-Executive Director Dec 2014
Mr Ohanessian has executive experience gained from technology-related businesses with a mixture of operational, strategic and leadership capabilities. Following a ten-year career at Mobil Oil, Mr Ohanessian joined the Boston Consulting Group where he consulted to clients in a wide range of industries which include banking, airlines, mining, packaging, sports, oil and gas, retailing and biotechnology. Mr Ohanessian later moved on to be the CEO of Vision BioSystems, a division of the former publicly listed Vision Systems Limited, where he transformed the business over seven years from a small unprofitable contract manufacturer into a vertically integrated, profitable and growing medical diagnostics business with distribution to over 60 countries. He has also served as Chief Executive of Genetic Technologies Limited and has been involved in investment management and corporate advice with Lion Capital. Mr Ohanessian then joined Praemium Limited, a company listed on the ASX as its CEO on 9 August 2011 until his recent resignation from Praemium Limited on 20 May 2021
Mr Andrew McLellan Chief Executive OfficerManaging Director Jan 2015
Mr McLellan has vast experience in innovation and commercialisation combined with significant technical and operational experience. Prior to joining Bluechiip, he was the CEO of Advanced Manufacturing Cooperative Research Centre (AMCRC) which he now serves as a non- executive Director. Mr McLellan focused on bringing together industry and research to develop and commercialise ground breaking innovations. He has held a range of senior positions including Director at Leica Microsystems Pty Ltd (previously Vision BioSystems Pty Ltd, a division of the former publicly listed Vision Systems Limited), Vice President of Marketing and Business Development North America and Director of Product Management at Vision BioSystems Pty Ltd
Mr Andrew Cox Non-Executive Director Jul 2017
Mr Cox is a finance professional with experience in emerging and international markets. Mr Cox was a co-founder and former chairman of private equity-funded media/ technology business Inlink (sold to ASX-listed oOh! Media Ltd in 2015), and is a co-founder of iPro Pty Ltd. Mr Cox began his career with KPMG in Melbourne before moving to China and Hong Kong, where he spent seven years with SG Warburg, the Australian Trade Commission and Ernst & Young. He is a member of the Translation and Commercialisation Committee of the Murdoch Children's Research Institute and is fluent in Mandarin Chinese
Ms Chelsea Sheridan Company Secretary Jan 2022
-
Chelsea Sheridan Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Hsbc Custody Nominees (Australia) Limited 61,156,093 10.23%
J P Morgan Nominees Australia Pty Limited 32,646,370 5.46%
Bellwether Investments Pty Ltd <York Street Settlement A/C> 29,276,974 4.90%
Mutual Trust Pty Ltd 21,564,454 3.61%
Dr Stephen Frederick Woodford 18,200,000 3.04%
Mr Iain Macgregor Crawford Kirkwood 15,024,949 2.51%
Radan Investments Pty Limited <Mcguirk Family A/C> 10,100,000 1.69%
Edward St Consulting Pty Ltd <Kirkwood Family S/Fund A/C 8,320,037 1.39%
Talento Holdings Pty Ltd 6,666,667 1.12%
Alltogether Pty Ltd <Alltogether Super Fund A/C> 6,001,322 1.00%
Ansata Investments Pty Ltd <Ansata Investment A/C> 5,674,087 0.95%
Mrs Amandeep Kaur 5,500,000 0.92%
Belladonna Holdings Pty Ltd <Belladonna Super Fund A/C> 5,460,601 0.91%
Mr Michael Bernard Ohanessian 4,983,400 0.83%
Zalpere Pty Ltd <R & D Zmood Super Fund A/C> 4,348,648 0.73%
Mr Michael Ohanessian & Mrs Candace Ohanessian <M & C Ohanessian S/F A/C> 4,264,335 0.71%
Bramscorp Pty Ltd <Gilbert Family S Fund A/C> 4,160,880 0.70%
Sulamerica Investments Pty Ltd <The Rooster Investment A/C> 3,932,391 0.66%
Edward St Consulting Pty Ltd <Kirkwood Family A/C> 3,752,746 0.63%
Roshi Red Pty Ltd <Roshi Red Super Fund A/C> 3,670,988 0.61%

Profile

since

Note